While combination antiretroviral therapy has meant that people with HIV can live longer lives, research shows that the virus makes fundamental changes to the immune system by increasing the risk of developing age-related ...
Sep 6, 2016
0
60
Though it has been eclipsed lately by SARS-CoV-2, there is another global epidemic still threatening people: HIV/AIDS. According to UNAIDS, a United Nations initiative, some 38 million people worldwide are currently infected ...
Mar 29, 2022
0
822
A single dose of an antibody-based treatment can prevent HIV transmission from mother to baby, new nonhuman primate research suggests for the first time. The findings are being published in the journal Nature Communications.
Jan 7, 2020
0
3206
An immunomodulatory drug called fingolimod, which is approved for the treatment of multiple sclerosis, blocks human immunodeficiency virus (HIV) infection and transmission in human immune cells, according to a study published ...
Aug 13, 2020
0
47
A new study published today in Nature Communications shows a promising alternative for those who have to take a daily pill regimen. Targeting HIV treatment and prevention, researchers across multiple departments at the University ...
Sep 20, 2019
0
281
Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers in the body, threatening to rise to dangerous levels ...
Sep 26, 2018
0
95
A laboratory study led by scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), lends further weight to the potential effectiveness of passive immunotherapy ...
Aug 26, 2014
0
0
The HIV Prevention Trials Network 052 study, led by Myron S. Cohen, MD of the University of North Carolina at Chapel Hill, has been named the 2011 Breakthrough of the Year by the journal Science.
Dec 22, 2011
3
0
Antiretroviral therapy has made HIV a manageable condition, but it does not eliminate the virus from the body—and most regimens are expensive and require a pill every day, for the rest of the patient's life.
Apr 19, 2022
0
28
An international study led by MELIS-UPF researchers from the Infection Biology and Molecular Virology laboratories has identified and characterized Schlafen 12 (SLFN 12) as a novel HIV restriction factor. SLFN 12 shuts down ...
May 10, 2023
0
82
